print_label | resize_label

THE ASTRAZENECA TYPE 2 DIABETES HUB FOR HEALTHCARE PROFESSIONALS

A range of Type 2 diabetes treatments to help you personalise your care

A highly selective SGLT2 inhibitor for insulin-independent removal of excess glucose via the kidneys.

Find out more about FORXIGA® (dapagliflozin) and XIGDUO® (dapagliflozin + metformin).

A GLP-1 receptor agonist for Type 2 diabetes patients who require convenient, flexible, once-weekly dosing.

Find out more about BYDUREON® (exenatide 2 mg powder and solvent for prolonged release suspension for injection)

A DPP-4 inhibitor that offers the confidence of CV safety data based on the largest CV outcomes trial to date.

Find out more about ONGLYZA® (saxagliptin) and KOMBOGLYZE® (saxagliptin + metformin).